nach oben

Erschienen in:

01.11.2010 | Original Article

Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life

verfasst von: Karis Kin-Fong Cheng, S. F. Leung, Raymond H. S. Liang, Josepha W. M. Tai, Rebecca M. W. Yeung, David R. Thompson

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

This study determined the incidence of severe oral mucositis (OM), patients’ self-reported moderate and severe oral symptoms, and change of quality of life (QoL), as well as examined whether OM severity and pain scores predicted the impairment of oral function and QoL.

Patients and methods

A multicenter approach was used and 137 patients treated with stomatotoxic chemotherapy (45%), high-dose myeloablative chemotherapy with or without concomitant total body irradiation (12%), head and neck irradiation with or without concomitant chemotherapy (44%) completed the OM-specific QoL measure (OMQoL) once or twice weekly over a 4- or 10-week period, along with concurrent measures of OM using WHO Mucositis Grading System and oral symptoms using 10 cm visual analog scale.

Main results

The incidence of severe OM was 50% (n = 68). About 77–80% of patients with severe OM reported moderate or severe mouth or throat pain, and 66–78% reported moderate or severe oral functional problems. The oral symptoms peak and area-under-the-curve (AUC) scores of patients with severe OM (peak 5.6 to 6.8; AUC 3.8 to 5.2) were significantly higher than those without OM and those with mild OM (p < 0.01). The OMQoL subscales peak and AUC scores of patients with severe OM (peak 47.9 to 62.1; AUC −40.1 to −25.8) were significantly lower than those without OM and those with mild OM (p < 0.01). Of those with severe OM, 88–94% had a drop in the OMQoL subscale scores to at least 10 points from the baseline. Pain resulting from OM, in particular throat pain, is most predictive of oral functional impairment (standardized β = 0.53–0.83).

Conclusions

Severe OM can cause profound pain and oral functional incapability and clinical significant impairment of QoL.

Scully C, Sonis S, Diz PD et al (2006) Oral mucositis. Oral Dis 12:229–241CrossRefPubMed

Cella D, Pulliam J, Fuchs H et al (2003) Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 98:406–412CrossRefPubMed

Cheng KKF (2007) Oral mucositis, dysfunction, and distress in patients undergoing cancer therapy. J Clin Nurs 16:2114–2121CrossRefPubMed

Spielberger R, Stiff P, Bensinger W et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. New Engl J Med 351:2590–2598CrossRefPubMed

Stiff PJ, Erder H, Bensinger WI et al (2006) Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 37:393–401CrossRefPubMed

Epstein JB, Beaumont JL, Gwede CK et al (2007) Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer 109:1914–1922CrossRefPubMed

Kushner JA, Lawrence HP, Kiss TL et al (2008) Development and validation of a Patient-Reported Oral Mucositis Symptom (PROMS) Scale. JCDA 74(1):59a–59j

Cheng KKF, Leung SF, Thompson DR et al (2007) A new measure of health-related quality of life for patients with oropharyngeal mucositis (OMQoL): development and preliminary psychometric evaluation. Cancer 109:2590–2599CrossRefPubMed

Cheng KKF, Leung SF, Liang RHS et al (2008) A patient-reported outcome instrument to assess the impact of oropharyngeal mucositis on health-related quality of life: a longitudinal psychometric evaluation. Support Care Cancer 17(4):289–298

10.

Osoba D, Rodrigues G, Myles J et al (1998) Interpretating the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed

11.

Engels JM, Diehr P (2003) Imputation of missing of longitudinal data: a comparison of methods. J Clin Epidemiol 56:968–976CrossRefPubMed

12.

Elting LS, Keefe DM, Sonis ST et al (2008) Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113:2704–2713CrossRefPubMed

13.

Nonzee NJ, Dandade NA, Markossian T et al (2008) Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis. Cancer 113:1446–1452CrossRefPubMed

14.

Trottii A, Bellm LA, Epstein JB et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262CrossRef

15.

Trotti A, Garden A, Warde P et al (2004) A multinational, randomized phase III trial of iseganan HCI oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 58:674–681PubMed

16.

Rosen LS, Abdi E, Davis ID et al (2006) Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 24:5194–5200CrossRefPubMed

17.

Anderson KO, Giralt SA, Mendoza TR et al (2007) Symptom burden in patients undergoing autologous stem-cell transplanation. Bone Marrow Transplant 39:759–766CrossRefPubMed

18.

Josting A, Sieniawski M, Glossmann JP et al (2005) High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin’s lymphoma: results of a multicenter phase II study. Ann Oncol 16:1359–1365CrossRefPubMed

19.

Blijlevens N, Schwenkglenks M, Bacon P et al (2008) Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy – European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 26:1519–1525CrossRefPubMed

20.

Moreau P, Facon T, Attal M et al (2002) Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du. Myeloma 9502 randomized trial. Blood 99:731–735CrossRefPubMed

21.

Horsley P, Bauer JD, Mazkowiack R et al (2007) Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer 15:105–109CrossRefPubMed

22.

Robien K, Schubert MM, Lloid ME et al (2004) Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 22:1268–1275CrossRefPubMed

23.

Isitt J, Murphy BA, Beaumont JL et al (2007) Oral mucositis-related morbidities and resource utilization in a prospective study of head and neck cancer patients. J Support Oncol 5:54–55

24.

Rosenthal DI, Mendoza TR, Chambers MS et al (2008) The M.D. Anderson Symptom Inventory – head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys 72:1355–1361PubMed

25.

Keefe DM, Rassias G, O’Neil L et al (2007) Severe mucositis: how can nutrition help? Curr Opin Clin Nutr Metab Care 10:627–631CrossRefPubMed

26.

Elting LS, Cooksley C, Chambers M et al (2003) The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531–1539CrossRefPubMed

27.

FallDickson JM, Ramsay ES, Castro K et al (2007) Oral mucositis-related oropharyngeal pain and correlative tumor necrosis factor-alpha expression in adult oncology patients undergoing hematopoietic stem cell transplantation. Clin Ther 29(Suppl):2547–2561CrossRef

28.

Epstein JB, Epstein JD, Epstein MS et al (2006) Oral doxepin rinse: the analgesic effect and duration of pain reduction in patients with oral mucositis due to cancer therapy. Anesth Analg 103:465–470CrossRefPubMed

29.

Bellm LA, Epstein JB, Rose-Ped P et al (2000) Patient reports of complications of bone marrow transplantation. Support Care Cancer 8:33–39PubMed

30.

Borbasi S, Cameron K, Quested B et al (2002) More than a sore mouth: patients’ experience of oral mucositis. Oncol Nurs Forum 29:183–205CrossRef

Titel: Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life
verfasst von: Karis Kin-Fong Cheng
S. F. Leung
Raymond H. S. Liang
Josepha W. M. Tai
Rebecca M. W. Yeung
David R. Thompson
Publikationsdatum: 01.11.2010
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 11/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-009-0771-7

Springer Medizin

Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life